ANI Pharmaceuticals (ANIP)
(Real Time Quote from BATS)
$66.37 USD
-0.97 (-1.44%)
Updated May 14, 2024 10:05 AM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for ANI Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 221 | 53 | 100 | 8 | 62 |
Receivables | 162 | 165 | 129 | 96 | 72 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 111 | 105 | 82 | 61 | 48 |
Other Current Assets | 25 | 20 | 11 | 6 | 5 |
Total Current Assets | 520 | 344 | 322 | 170 | 188 |
Net Property & Equipment | 45 | 43 | 53 | 41 | 41 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 91 | 81 | 68 | 52 | 38 |
Intangibles | 237 | 280 | 322 | 192 | 184 |
Deposits & Other Assets | 12 | 11 | 7 | 6 | 6 |
Total Assets | 904 | 760 | 772 | 461 | 457 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 37 | 29 | 23 | 11 | 15 |
Current Portion Long-Term Debt | 1 | 1 | 1 | 13 | 10 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 88 | 69 | 64 | 50 | 37 |
Income Taxes Payable | 8 | 0 | 0 | 4 | 0 |
Other Current Liabilities | 12 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 145 | 99 | 88 | 79 | 62 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 285 | 286 | 287 | 172 | 176 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 17 | 36 | 39 | 14 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 447 | 422 | 413 | 265 | 244 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 25 | 25 | 25 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 514 | 404 | 388 | 214 | 201 |
Retained Earnings | -80 | -97 | -48 | -5 | 18 |
Other Equity | 9 | 12 | -3 | -11 | -5 |
Treasury Stock | 10 | 5 | 3 | 2 | 1 |
Total Shareholder's Equity | 458 | 339 | 359 | 196 | 213 |
Total Liabilities & Shareholder's Equity | 904 | 760 | 772 | 461 | 457 |
Total Common Equity | 433 | 314 | 334 | 196 | 213 |
Shares Outstanding | 20.48 | 17.51 | 16.90 | 12.30 | 12.10 |
Book Value Per Share | 21.13 | 17.91 | 19.76 | 15.91 | 17.59 |
Fiscal Year End for ANI Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 238 | 221 | 193 | 162 | 68 |
Receivables | 172 | 162 | 179 | 173 | 175 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | 114 | 111 | 107 | 104 | 104 |
Other Current Assets | 16 | 25 | 19 | 20 | 19 |
Total Current Assets | 541 | 520 | 497 | 459 | 365 |
Net Property & Equipment | 49 | 45 | 44 | 44 | 43 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | 88 | 91 | 84 | 82 | 81 |
Intangibles | 224 | 237 | 248 | 259 | 267 |
Deposits & Other Assets | 14 | 12 | 16 | 16 | 9 |
Total Assets | 915 | 904 | 890 | 859 | 765 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 49 | 37 | 34 | 29 | 33 |
Current Portion Long-Term Debt | 1 | 1 | 1 | 1 | 1 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 75 | 88 | 75 | 68 | 70 |
Income Taxes Payable | 11 | 8 | 1 | 0 | 0 |
Other Current Liabilities | 0 | 12 | 24 | 25 | 23 |
Total Current Liabilities | 137 | 145 | 134 | 123 | 126 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | 285 | 285 | 285 | 285 | 285 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16 | 16 | 17 | 14 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 438 | 447 | 435 | 425 | 426 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 25 | 25 | 25 | 25 | 25 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 524 | 514 | 507 | 495 | 408 |
Retained Earnings | -62 | -80 | -81 | -90 | -96 |
Other Equity | 9 | 9 | 14 | 14 | 11 |
Treasury Stock | 19 | 10 | 10 | 9 | 9 |
Total Shareholder's Equity | 477 | 458 | 455 | 434 | 339 |
Total Liabilities & Shareholder's Equity | 915 | 904 | 890 | 859 | 765 |
Total Common Equity | 452 | 433 | 430 | 410 | 315 |
Shares Outstanding | 21.08 | 20.48 | 20.40 | 20.30 | 18.00 |
Book Value Per Share | 21.44 | 21.13 | 21.07 | 20.18 | 17.48 |